Navigation Links
FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
Date:11/20/2007

er claims approximately 55,000 lives each year, the vast majority of which are a result of recurrent metastatic disease. Metastatic colorectal cancer occurs when tumor cells spread to other locations in the body and grow. Although there are several options for the treatment of metastatic colorectal cancer, oncologists often have to wait several months before they can determine if a specific treatment is beneficial to the patient. The CellSearch(TM) System helps physicians to predict disease progression and patient survival any time during therapy through its ability to locate minute numbers of circulating tumor cells in the approximately 40 billion cells contained in a 7.5 ml sample of blood - an achievement never before documented in any diagnostic tool.

The CellSearchTM System was originally cleared by the FDA in January 2004 as a diagnostic tool for identifying and counting CTCs in a blood sample to predict progression-free survival and overall survival in patients with metastatic breast cancer.

A prospective, multi-center clinical trial was conducted to validate the expanded clearance for CellSearch. The study, which took place in 55 clinical centers in the United States and Europe, involved 430 metastatic colorectal patients about to enter first- or second-line therapy. Data showed that patients with less than three CTCs at baseline had significantly better survival rates versus patients with more than three CTCs - an overall finding consistent with metastatic breast cancer patients. Data also showed that CTCs are a strong independent predictor of progression-free survival and overall survival, and that the combination of CTC analysis and radiological assessment may provide the most accurate assessment of prognosis.

"Clinical research validates the significance of circulating, cancer tumor cells," said Robert McCormack, Ph.D., Vice President of Medical and Scientific Affairs, Veridex. "Elevated CTCs in the blood stream are associated with l
'/>"/>

SOURCE Veridex, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 14, 2011 Regulus Therapeutics Inc ., a ... medicines targeting microRNAs, today announced that it has added ... The addition of Dr. Hannon, a researcher whose work ... microRNA pathway, increases SAB membership to six pioneers in ...
... Renal Therapies Division of B. Braun Medical ... Plasmat™ Futura System for H.E.L.P. ®   LDL Apheresis ... therapy provides a more easy-to-use system for clinicians ... severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... TN (PRWEB) January 22, 2015 Gabe’s Chemo Duck ... Duck App, the first app ever created for kids with cancer. ... Apple phones and devices, is filled with enjoyable games to help ... and treatments. The free app helps to keep kids entertained, educated ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... diseases, including Age-Related Macular Degeneration and Diabetic ... ... Charlesson, LLC ("Charlesson"),today announced that it is the recipient of several ... and an award from the Oklahoma Center for the Advancement of ...
... -- In the 25 years since establishing the Dyslexia ... Albert Galaburda, MD, has witnessed a dramatic transformation in ... Over the years, there have been a host of ... the Division of Behavioral Neurology at BIDMC whose work ...
... - Solaris Platform is Now Supported to Help ... Supporting growing,demand within the biomedical market for ... the availability of Release 1.3,of SLIM Search. The ... and sensitivity for biomedical research and development.,Version 1.3 ...
... Food for Kids with Diabetes" by Robyn Webb, ... a child with diabetes,doesn,t have to mean making ... http://www.clevelandclinicpress.org/ ), publishing arm of Cleveland,Clinic ( http://www.clevelandclinic.org/ ... for Kids with Diabetes" by award-winning nutritionist and,columnist ...
... (Nasdaq: IMCL ) and Bristol-Myers Squibb Company ... established an agreement with Merck KGaA for,the co-development ... terms of the agreement, ImClone Systems, Bristol-Myers,Squibb and ... to develop and,following regulatory approval, market ERBITUX in ...
... aureus Infections in the, United States, shows that hospital-caused MRSA infections are ... have,consistently understated the size of the problem and have failed to call ... from these ... infections., NEW YORK, Oct. ...
Cached Medicine News:Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 2Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 3Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 4Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 5Health News:BIDMC Dyslexia Research Lab celebrates 25th anniversary 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:New Cleveland Clinic Press Healthy Cookbook Helps Diabetic Kids 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 3Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 4Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 5Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 6Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 7Health News:The Journal of the American Medical Association (JAMA) Article Reveals Scope of MRSA Infections 2
Bruns bone curette, 9, oval, solid actagonal handle....
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
9.5" overall length, 4.5" handle....
Medicine Products: